Lv1
50 积分 2021-08-02 加入
Targeting cancer with small molecule pan-KRAS degraders
15天前
已完结
Tubulysins as Antibody–Drug Conjugate (ADC) Payloads
2个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
2个月前
已完结
Continuous Processing for Manufacturing of Antibody–Drug Conjugates (ADCs)
2个月前
已完结
Toward the Establishment of a Harmonized Physicochemical Profiling Platform for Therapeutic Oligonucleotides: A Case Study for Aptamers Where the Higher-Order Structure Influences Physical Properties
3个月前
已完结
Kinetic Modeling of Solid-Phase Oligonucleotide Synthesis: Mechanistic Insights and Reaction Dynamics
4个月前
已完结
miR-296-5p suppresses stem cell potency of hepatocellular carcinoma cells via regulating Brg1/Sall4 axis
4个月前
已完结
Small-Molecule Inhibitors of Mas-Related G Protein-Coupled Receptor X2 (MRGPRX2)
5个月前
已完结
Radioactive ADME Demonstrates ARV-110’s High Druggability Despite Low Oral Bioavailability
5个月前
已完结
Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges
5个月前
已完结
皖公网安备34019202002308
